Aegon and Allianz have invested a total of no less than 11 billion euros in 19 pharmaceutical companies in 2019 without encouraging them to reduce high drug prices. These insurers also lack the commitment to prevent tax avoidance by pharmaceutical giants. This is the conclusion of a new study by the Fair Insurance Guide into investments by insurers in pharmaceuticals, conducted by SOMO.
Peter Ras, spokesperson for the Fair Insurance Guide:
“Affordable medication is of vital importance, especially for poor people in the Netherlands and in developing countries. Insurers have to increase their pressure on pharmaceutical companies to make affordable medicines and pay their fair share of taxes.”
Read the whole article in Dutch.
The Fair Insurance Guide is a collaboration between Amnesty International, FNV, Milieudefensie, Oxfam Novib, PAX and World Animal Protection. The nine insurers all participated in this investigation and were given the opportunity to respond to the investigation findings.